Introduction
Genetic liability to schizophrenia involves a combination of rare and common risk alleles distributed across the genome 1 . Common schizophrenia risk alleles with odds ratios < 1.3 account for at least a third of genetic liability [2] [3] [4] , although only a small fraction of this is 4 captured by the 145 genome-wide significant loci that were implicated in the largest published genome-wide association study (GWAS) of the disorder 5 . At the other end of the frequency spectrum, rare copy number variants (CNVs) and rare coding variants (RCVs), both sometimes occurring as de novo variants (DNVs), have been implicated in the disorder 6, 7 . Although CNVs and RCVs are enriched in schizophrenia, not all rare variants observed in individuals with schizophrenia, including those occurring de novo, are expected to be aetiologically relevant, as there is a baseline burden of these variants in the general population.
In people with other neurodevelopmental disorders (NDDs) in which CNVs and RCVs play a role, particularly autism spectrum disorder (ASD) 8, 9 and developmental delay (DD) 10,11 , the enrichment for RCVs is greatest in genes classified as intolerant to loss-of-function (LoF) variants (i.e. variants that introduce premature stop codons or frameshifts in the encoded protein, or are predicted to disrupt mRNA splicing). This indicates that RCVs in these genes are more likely to be pathogenic for those disorders than RCVs occurring elsewhere in the genome. Moreover, greater enrichment is found for LoF DNVs than for missense DNVs that change an encoded amino acid, indicating the former class of mutation is particularly likely to be pathogenic. Similar observations have been made in schizophrenia, where an excess of LoF DNVs was found to be largely restricted to LoF intolerant genes 7 , although the degree of enrichment is lower than for ASD or DD.
In studies of ASD and DD, a significant excess of RCVs has been observed for 99 and 94
genes, respectively, with 32 of these genes overlapping between these disorders 8, 10 . Only two genes, SETD1A 12 and RBM12 13 , are currently associated with RCVs in schizophrenia. This is partly because of lower statistical power, as the number of trios that have been exome-5 sequenced in studies of schizophrenia (n=2,834) is smaller than equivalent studies of DD (n=7,580) 10 and ASD (n = 6,430) 8 , but it also reflects the weaker enrichment in schizophrenia for this type of variant. As a set, genes disrupted by DNVs in NDDs are also enriched for DNVs in schizophrenia 14, 15 , and therefore it follows that some of the genes implicated in ASD and DD by RCVs are also involved in the aetiology of schizophrenia. Aiming to contribute to the schizophrenia rare variant discovery effort, we have undertaken exomesequencing in a new sample of 613 schizophrenia trios, and combined our data with published data from 2,834 trios, which includes 617 trios previously sequenced by our group 14 , to provide the largest analysis of coding DNVs in schizophrenia to date. Given the anticipated modest power even of this sample, as we have successfully done before for CNV analysis 16 , we exploited the well documented overlap in the genetic aetiologies of schizophrenia, ASD, and DD, to undertake a hypothesis focused analysis of NDD genes in schizophrenia which highlights SLC6A1 as a novel risk gene.
The involvement of common variant polygenic risk in schizophrenia is already established 2,4,17 , but few existing studies have empirically examined the relationships between different classes of rare and common variants. In schizophrenia, the evidence indicates that rare CNVs and common risk variants co-act and do so in an additive manner 18, 19 . Thus, affected carriers of schizophrenia-associated CNVs have been shown to have an elevated burden of common schizophrenia risk alleles as measured by the polygenic risk score (PRS), and this is inversely proportional to the estimated effect size of the implicated CNV 18 .
Analogous observations have been made in ASD and DD, where common variant polygenic risk for those disorders has been shown to be over-transmitted from parents to probands, even in those that carry a disorder-associated DNV 20, 21 . However, as yet, the relationship between rare exonic DNVs and common allele risk has not been studied in schizophrenia. Here, we 6 examine this relationship using the polygenic transmission-disequilibrium test (pTDT) 21 .
Specifically, we show that people with schizophrenia who are carriers of DNVs in gene sets proposed to be relevant to schizophrenia have a lower common risk allele burden than people with schizophrenia who are not carriers.
Methods
Sample overview 674 schizophrenia proband-parent trios, consisting of 2,000 individuals, were exomesequenced on Illumina HiSeq 4000 platforms. The proband-parent trios were composed of 653 trios, 9 quads (two affected children) and one family with 3 affected children. None of these samples have been previously exome-sequenced. The proband-parent trios were ascertained from sites in Europe (Supplementary Table S1 ), each of which is described fully in the Sample Description section of the Supplementary Material. All probands had received a DSM-IV or ICD-10 diagnosis of schizophrenia.
Exome sequence generation
Exome sequence was generated using the Nextera DNA Exome capture kit and HiSeq 3000/4000 PE Cluster Kit and HiSeq 3000/4000 SBS Kit. Raw sequencing reads were processed according to GATK best practice guidelines 22, 23 . Reads were aligned to the human reference genome (GRCh37) using bwa version 0.7.15 24 . Variants were called using GATK haplotype caller (v3.4) and filtered using the GATK Variant Quality Score Recalibration (VQSR) tool. For all samples passing QC (criteria outlined below), we generated sequence data for a median of 83% of the exome target at ≥ 10X coverage.
Sample quality control 7 Trios (n=27) were excluded for low sequencing coverage if less than 70% of the exome target achieved ≥ 10X coverage in the proband or either parent (Supplementary Figure S1 ). An additional 27 trios were excluded for excess heterozygosity (heterozygote:homozygote ratio > 1.9) or evidence of cross sample contamination (as measured by the FREEMIX sequence only estimate of contamination 25 ) (Supplementary Figure S2) . The last two metrics are highly correlated. Identity-by-descent (IBD) analysis (plink v1.9) to ensure expected proband-parent relationships resulted in exclusion of 3 trios. Four additional trios were excluded as outliers for the number of DNVs (Supplementary Figure S3) . Following implementation of all the above sample QC steps, 613 proband-parent trios were retained for DNV analysis.
Variant QC Table S3 ).
Adding published de novo data
To increase the power of our analysis, we included previously published DNVs from 2,831 schizophrenia trios. When combined with our new trios, this resulted in a sample size of 3,444 schizophrenia trios. A summary of the published data can be found in Supplementary   Table S4 .
De novo variant analysis
We tested whether DNVs were enriched in single genes or sets of genes using the statistical framework described in Samocha et al 2014 26 . Here, for a given set of genes we estimated the number of DNVs expected in our new sample using per-gene mutation rates 27 , adjusted for sequence coverage. When estimating the number of expected DNVs in previously published 9 trios, we did not adjust per-gene mutation rates for coverage as coverage metrics were not available for all samples; the use of unadjusted per-gene mutation would over-estimate the expected number of DNVs in these trios, producing more conservative enrichment results.
For single genes, we tested whether the overall burden of DNVs was significantly greater than that expected using a one-sided Poisson test (implemented in R). For our primary de novo gene set analysis, we controlled for background de novo rates by using a two-sample Poisson rate ratio test, which compared the DNV enrichment observed for genes in the set to that in genes outside the set. , if an individual carried multiple de novo variants in the same gene, we conservatively considered these to be the result of a single mutation event, and retained for analysis only the variant predicted to be most deleterious.
Polygenic risk scores
Where available (n=1,122 trios), we used SNP genotype data to generate polygenic risk scores. We confirmed that genotype and exome-sequence data belonged to the same individual through IBD analysis (plink v1.9). A summary of the data sets for which we had both exome-sequencing and SNP genotype data can be found in Supplementary Table S5 .
Using the largest available GWAS summary statistics that were independent from our trio test data, we derived PRS for schizophrenia, bipolar disorder (BD) and type 2 diabetes (T2D).
We used BD PRS as previous studies have shown that common variant liability to schizophrenia and BD is substantially shared
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. T2D PRS was used as a negative control. A summary of the training data used to generate PRS can be found in Supplementary Table S5 .
For QC purposes, SNP genotype data were first harmonised to the Haplotype Reference Consortium panel using the Genotype Harmonizer package 31 and then subjected to standard quality control, which included exclusion of samples with a call rate < 95%, SNPs with a MAF < 0.1, SNPs with > 1% missingness, or SNPs with a Hardy-Weinberg equilibrium exact test p value < 1 x 10 -6
. PRS were generated using PRSice 2 software 32 , where SNPs were clumped based on a window of 250 kb and a maximum r 2 of 0.2. We generated PRS across a range of training data P-value thresholds (P < 0.5, 0.1, 0.05, 0.001).
pTDT deviation
To test for a significant over-transmission of polygenic risk, we used the polygenic transmission disequilibrium test (pTDT) as described in Weiner et al (2017) 21 . Here, pTDT deviation scores were generated for each trio by subtracting the mean-parental PRS from the child PRS (Equation 1). pTDT deviation scores were standardised by dividing them by the cohort-specific mean-parental PRS standard deviation.
We tested whether the mean pTDT deviation was significantly greater than 0, representing an over-transmission of polygenic risk, by using a one-sided one-sample t test. A two-sample t test was used to compare mean pTDT deviation scores across groups of trios.
The primary pTDT results were produced using PRS generated with a P-threshold of 0.05, as this threshold explained the most case-control variance in the 2014 schizophrenia PGC analysis 4 . However, we also present in the Supplementary Material Table S6 pTDT results obtained for PRS generated across different P-value thresholds.
Results

De novo mutation rates
After variant QC, we observed 606 coding de novo variants (DNVs) in 613 probands (Supplementary Table S3 ), corresponding to a rate of 0.99 (s.e = 0.041) events per proband, which is not significantly different to the rate observed in a sample of 617 schizophrenia trios previously published by our group 14 (previous de novo rate = 1.032; rate ratio (RR) (95% confidence interval (CI)) = 0.96 (0.86, 1.07); p = 0.46). Of these coding DNVs, 154 were synonymous, 372 were missense, 15 were inframe indels, 2 start-loss, 1 stop-lost, and 62
were LoF (19 stop-gain, 13 splice and 30 frameshift indels). The number of coding DNVs observed per-trio followed the expected Poisson distribution (Supplementary Figure S4) .
De novo variant enrichment tests
In the new data set, we observed a significant excess of LoF DNVs among LoF intolerant ; Supplementary Table S7 ). DNVs were tested in LoF intolerant genes and neurodevelopmental disorder (NDD) genes.
For LoF intolerant and NDD gene sets, rate ratios and 95% confidence intervals are relative to the baseline DNV rate, which is defined as the LoF DNV enrichment observed for all genes outside of the given set. LoF DNV enrichment for LoF tolerant genes are shown as a negative control. A breakdown of the LoF intolerant and NDD gene set results is provided in Supplementary Tables S7 and S8 .
In the combined trio data, no individual gene was significantly enriched for LoF DNVs after correction for all genes tested (n=18,658). The most significant novel gene was CUL1, which 13 had two LoF DNVs in the new trios and one additional LoF DNV in the published trios (Table 1) . 14 Exploiting the strong enrichment among NDD genes for DNVs in schizophrenia, we undertook focused analysis of genes in this set, with the aim of identifying high probability schizophrenia risk genes. As highlighted in the study of ASD 8 , association to some NDD genes is driven by LoF variants alone, a combination of LoF variants and missense variants, and in some cases, primarily by missense variants. Therefore, we considered all those classes of mutation in our analysis. All LoF/missense-damaging DNVs observed in NDD genes and, where available, phenotypes observed in these carriers are presented in Supplementary Table   S9 .
SLC6A1 was significantly associated with missense-damaging DNVs in our new trio data after correcting for three classes of mutation (LoF, missense-damaging and LoF plus missense-damaging) and 160 NDD genes (2 damaging-missense DNVs; p = 7.46 x 10 -5 ;
p corrected = 0.036). This finding was supported in our analysis of all trio data, where we observed one additional missense-damaging DNV ( ; Fig 3) .
Based on mean pTDT point estimates, the over-transmission of common risk alleles from parents is about 7-fold greater to non-carriers than carriers of candidate schizophrenia related DNVs, although this estimate is imprecise given the width of the confidence intervals (Fig 3) .
Similar patterns were observed when LoF and deletion DNVs were tested separately (Fig 3) .
In a negative control test, the mean pTDT did not significantly differ between probands carrying a synonymous DNV in either a LoF intolerant or NDD gene and non-carriers (Fig   3) . The finding that the mean pTDT deviation for schizophrenia PRS was significantly different between probands carrying candidate schizophrenia related DNVs and non-carrying probands was consistent across schizophrenia PRS training p-value thresholds (Supplementary Table   S11 ). Although the pTDT method is expected to be robust to population stratification, the efficacy of PRS as a measure of relative liability varies with the extent to which the ancestry of the sample from which risk alleles are derived (the source GWAS) matches the ancestry of those being tested (in our case the trios). Given the source GWAS is primarily of European ancestry, we tested, and confirmed, that our findings held when we restrict our analysis to trios with European ancestry (as defined by PCA; Supplementary Figure S5 ) despite the smaller sample size (Supplementary Table S11 ).
The mean pTDT in carriers of candidate schizophrenia related DNVs was not significantly greater than the null (Fig 3) . Based on the pTDT standard deviation observed for schizophrenia PRS in all trios (0.89), we only had 80% power to detect a significant (alpha = 0.05) mean pTDT of 0.4 in the 63 carriers of candidate schizophrenia related DNVs. Thus, while we can be confident that the over-transmission to candidate DNV carriers is less than to carriers, power limitations mean we cannot conclude that candidate DNV carriers have no contribution from common alleles.
Discussion
Proband-parent trio studies have identified large numbers of genes associated with DNVs in ASD and DD 8, 10 . Although similar studies in schizophrenia have revealed general pathophysiological insights into the disorder, such as a role in the disorder for proteins involved in postsynaptic signaling complexes 14, 34 , schizophrenia gene discovery through DNV analysis has been hindered by small samples. To add to efforts to overcome this limitation, we performed exome-sequencing of a new sample of 613 schizophrenia trios. We confirmed previous work showing schizophrenia LoF DNVs are significantly enriched among a set of 3,488 genes intolerant to this class of mutation, and identified a stronger enrichment of DNVs in a smaller set of 160 genes that are associated with RCVs in NDDs.
In our analysis of all schizophrenia trios, no novel gene was unequivocally associated with . Given the strong convergent evidence for this gene, and specifically for a role for missense mutations, from other NDDs, SLC6A1 is highly likely also to be involved in schizophrenia. This conclusion is further supported by the result of the DNV missense metaanalysis of ASD and schizophrenia, in which the combined evidence for association is more than 3 orders of magnitude stronger than the (already strong) evidence for association to ASD alone, and surpasses genome-wide significance by 8 orders of magnitude.
The role of polygenic risk in schizophrenia has been widely studied using large case-control samples. However, to our knowledge, this is the first study to investigate polygenic risk in schizophrenia using the pTDT method. The pTDT method has several advantages over casecontrol PRS studies as it is not confounded by ancestry or ascertainment bias or the possibility of effects arising from super-healthy controls in discovery GWAS and subsequent PRS test samples 21 . Our results provide strong refutation that such effects might explain the PRS effects that have been widely publicised in the literature, including that of overlap in risk 21 between schizophrenia and BD. More importantly in the present context, our finding that carriers of LoF DNVs in the large gene set defined by LoF intolerance, or in a known NDD gene, have significantly lower distortion of transmission of polygenic liability from the mean parental PRS than do non-carriers provides orthogonal evidence that a substantial proportion of this class of variants contribute to schizophrenia pathogenesis. This is an important observation given the possibility that previously documented gene set enrichments in cases of these variants could have been driven by errors in the calibration of the expected mutation rate, or technical issues arising from comparing cases and controls (or case and control trios) often derived opportunistically from different studies.
In terms of magnitude of difference in the transmission distortion between probands carrying candidate schizophrenia related DNVs and those that do not, our limited sample size does not allow this to be accurately estimated. The point estimate is that the distortion in non-carriers is about 7-fold of that of carriers (and almost 10-fold when restricted to those of European ancestry). This suggests that on average, the candidate DNVs contribute substantially to liability in those who carry them, indeed carriers of candidate schizophrenia related DNVs did not significantly over-inherit schizophrenia PRS when compared with chance. However, it is important to stress that the latter finding most likely reflects limited power rather than no role for common variation in the carriers; consistent with this interpretation, the point estimate for the pTDT in candidate DNV carriers is greater than 0. Nevertheless, it will be important for future work to determine whether differences in co-action between common and rare risk alleles exist between schizophrenia and NDDs.
In conclusion, we provide further evidence that certain classes of DNV are associated with increased risk for schizophrenia. We highlight strong evidence that mutations in SLC6A1, a 22 known ASD, DD and epilepsy gene, confer high risk of schizophrenia. Through combining exome-sequencing and GWAS data, we show that carriers of candidate schizophrenia related DNVs inherit significantly fewer common risk alleles than non-carrying cases, providing strong orthogonal evidence that these DNVs contribute to schizophrenia liability.
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